Coloplast A/S

Top-line & profitability: solid quarter; Biologics remains the main drag - Q3 (constant currencies, before special items): ~6% organic revenue growth and ~5% EBIT growth. - ROIC (after tax, before special items) ~15%, in line with prior level. - YTD (9 months): reported revenue +~3% (organic +~6%), but FX headwind ~-3 percentage points on reported growth.

Business performance: Chronic Care & Interventional Urology strong; Wound/Biologics pressured - Ostomy Care: +5% organic in Q3 (Europe/U.S./EM ex China +7%), driven by SenSura Mio convex; China had a temporary disruption from inventory/channel changes. - Continence Care: +8% organic in Q3; strong U.S./Europe; Luja main driver; Bowel Care strong double-digit. - Wound & Tissue Repair: +3% organic in Q3 but Biologics declined ~-6% in Q3 due to U.S. reimbursement reform (outpatient); inpatient “healthy”, with double-digit growth YTD. - Interventional Urology: +7% organic in Q3 (Men’s Health led); Titan delivering double-digit growth; Titan Prime received FDA approval (launch expected within “next couple of months”); Intibia U.S. timing deferred (see below).

Guidance/outlook for FY ’25/’26: unchanged, but currency and Biologics risks persist - Management kept full-year guidance unchanged: - Organic revenue growth: ~5%–6% - EBIT growth (constant currencies, before special items): ~+5% - ROIC (after tax, before special items): ~15% - Still expecting: - FX drag ~-2 to -3 percentage points on reported revenue growth - ~80 bps negative impact on reported EBIT margin - Raw material inflation assumptions: ~1% in H2 ’25/’26 and ~2–3% next year - Geared position: expect ~2.3x EBITDA gearing by fiscal year end.